Cilnidipine is an antihypertensive drug. It comes in a form of film-coated tablet and is available in three strengths, 5 mg, 10 mg and 20 mg.
It acts on the calcium channels of blood vessels and blocks the incoming calcium. This helps in suppressing the contraction of blood vessels, thereby reducing blood pressure. Cilnidipine dilates both arterioles and venules thus reducing the pressure.
The additional benefit of Cilacar is that it decreases blood pressure safely and effectively without excessive blood pressure reduction or tachycardia (an abnormally rapid heart rate).
It can also be used in elderly patients with diabetes and compromised renal function with chronic kidney disease.
Cilnidipine is launched in India by JB Chemicals & Pharmaceuticals Ltd. (JBCPL) in 2007. Established in 1976, JBCPL is one of India’s fastest growing pharmaceutical companies. It is an integrated, research-oriented organisation with a focus on supplying affordable, quality products both in India and International markets. JBCPL is trusted by healthcare professionals globally and operates in more than 30 countries across the world.
Cilacar is an orally available medication that contains Cilnidipine. It blocks the influx of calcium inside the blood vessels. This helps in relaxation and dilation of blood vessels thus reducing the blood pressure.
Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. High blood pressure is a major risk factor for coronary heart disease and a cause of heart attacks. A build-up of cholesterol is part of the process that narrows arteries, called atherosclerosis, in which plaques form and cause restriction of blood flow leading to high blood pressure.
In a hypertension patient, blood pressure is the force exerted by the blood against the walls of the blood vessels. Cilacar can be used to treat hypertension, which if unattended can cause a host of health problems and diseases that may include:
Cilacar has been proven to work well among patients with high blood pressure.
Hypotension, poor cardiac reserve, heart failure. Sudden withdrawal may exacerbate angina. Discontinue in patients who experience ischemic pain following administration. Pregnancy, lactation.
Other antihypertensives; aldesleukin; antipsychotics that cause hypotension; may modify insulin and glucose responses; quinidine; carbamazepine; phenytoin; rifampicin; cimetidine; erythromycin.
Mechanism of Action
Cilnidipine is a dihydropyridine calcium-channel blocker. It inhibits cellular influx of calcium, thus causing vasodilatation. It has greater selectivity for vascular smooth muscle. It has little or no action at the SA or AV nodes and -ve inotropic activity is rarely seen at therapeutic doses.